Sweden's CLS Q1 sales fall 72% after partner talks

About this update from Clinical Laserthermia Systems Ab Class B

OverviewSweden cancer therapy device maker's Q1 sales fell 72% yr/yr due to partner alignment talksQ1 operating profit declined, reflecting lower revenue, not higher expensesCompany secured SEK 23 mln purchase orders for Prism business after quarter endOutlookCLS expects 2026 revenue to show strong double-digit growth versus 2025, with H2 weightingCompany has secured purchase orders of about SEK 23 mln for the neurosurgery Prism businessCLS now expects positive cash flow from Q1 2028, updating previous guidance of Q4 2026Result DriversPARTNER ALIGNMENT TALKS - Sales of Prism products to neurosurgery partner were temporarily impacted by ongoing alignment discussions, leading to lower Q1 revenueCLINICAL MOMENTUM - Continued installations and procedure growth in U.S. neurosurgery market reflected underlying clinical and commercial momentumCOST CONTROL - Decline in operating profit reflected lower revenue, not increased expenses, as CLS maintained strict cost control and improved operational efficiencyCompany press release:Key DetailsMetricQ1 SalesBeat/MissActualSEK 1.30 mlnConsensus EstimateAnalyst CoverageWall Street's median 12-month price target for Clinical Laserthermia Systems AB is SEK9.00, about 86.3% above its May 11 closing price of SEK4.83For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

View stock analysis, news, and events for Clinical Laserthermia Systems Ab Class B